Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets

Palisade Bio offers a speculative early-stage opportunity, advancing PALI-2108, a gut-restricted PDE4 inhibitor for UC and Crohn’s disease. PALI-2108’s Phase 1 trials showed favorable safety, target engagement, and early clinical activity, supporting a differentiated mechanism of action. PALI’s $132.6 million cash runway funds operations through key Phase 2 efficacy readouts in 2027–2028, reducing near-term dilution risk. Comparable oral UC therapies achieved multi-billion dollar M&A valuations; if PALI-2108’s efficacy is replicated in larger trials, significant upside is possible.

Palisade Bio, Inc. (PALI) is an early-stage biotechnology company focused on developing a new class of PDE4 inhibitor prodrugs. Their lead asset, PALI-2108, recently received IND clearance and is set to initiate a Global